BlackRock Inc. bought a new stake in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,922,828 shares of the company's stock, valued at approximately $8,807,000. BlackRock Inc. owned approximately 3.89% of Whitehawk Therapeutics as of its most recent SEC filing.
Other hedge funds have also bought and sold shares of the company. Quadrature Capital Ltd bought a new position in Whitehawk Therapeutics in the 4th quarter valued at $28,000. OMERS ADMINISTRATION Corp bought a new position in Whitehawk Therapeutics during the first quarter valued at about $40,000. Dimensional Fund Advisors LP bought a new position in Whitehawk Therapeutics during the third quarter valued at about $84,000. Deutsche Bank AG purchased a new stake in Whitehawk Therapeutics during the second quarter worth about $145,000. Finally, Squarepoint Ops LLC purchased a new position in Whitehawk Therapeutics in the third quarter valued at about $159,000. 52.08% of the stock is currently owned by institutional investors.
Whitehawk Therapeutics Stock Performance
WHWK stock opened at $4.60 on Friday. Whitehawk Therapeutics, Inc. has a 52 week low of $1.76 and a 52 week high of $5.49. The firm's fifty day moving average is $4.30 and its 200 day moving average is $4.05. The firm has a market cap of $262.25 million, a P/E ratio of -4.11 and a beta of 0.81.
Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. As a group, analysts forecast that Whitehawk Therapeutics, Inc. will post -1.1 EPS for the current year.
Wall Street Analyst Weigh In
A number of research analysts have recently commented on WHWK shares. B. Riley Financial assumed coverage on Whitehawk Therapeutics in a research report on Thursday, June 25th. They set a "buy" rating and a $10.00 price target on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Whitehawk Therapeutics in a report on Wednesday. Wall Street Zen raised shares of Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th. Oppenheimer restated an "outperform" rating and set a $7.00 price target on shares of Whitehawk Therapeutics in a research note on Friday, May 8th. Finally, Leerink Partners started coverage on shares of Whitehawk Therapeutics in a report on Monday, July 13th. They issued an "outperform" rating and a $9.00 price objective for the company. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $8.20.
Check Out Our Latest Report on WHWK
Whitehawk Therapeutics Company Profile
(
Free Report)
Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Whitehawk Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Whitehawk Therapeutics wasn't on the list.
While Whitehawk Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
